# Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

> **NCT04971109** · PHASE3 · COMPLETED · sponsor: **SIGA Technologies** · enrollment: 467 (actual)

## Conditions studied

- Smallpox

## Interventions

- **DRUG:** TPOXX
- **OTHER:** TPOXX Placebo

## Key facts

- **NCT ID:** NCT04971109
- **Lead sponsor:** SIGA Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-29
- **Primary completion:** 2023-05-12
- **Final completion:** 2023-05-12
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04971109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04971109, "Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04971109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*